The role of epigenetic modification in tumorigenesis and progression of pituitary adenomas: A systematic review of the literature

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Pease, Matthew ^a   Ling, Chao ^a   Mack, William J ^a   Wang, Kai ^a   Zada, Gabriel ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8;

CANCER GROWTH; CARCINOGENESIS; CDKN2A GENE; CELL CYCLE PROGRESSION; DAPK GENE; DNA METHYLATION; EPIGENETICS; FGFR2 GENE; GADD45Y GENE; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; GENOME IMPRINTING; GNAS1 GENE; HISTONE ACETYLATION; HISTONE MODIFICATION; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; MAGE A3 GENE; MEG3 GENE; ONCOGENE; P27 GENE; PROTEIN MODIFICATION; PTAG GENE; RASSF1A GENE; RB1 GENE; REVIEW; SYSTEMATIC REVIEW; TRANSCRIPTION REGULATION;

APOPTOSIS REGULATORY PROTEINS; CASPASE 8; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; PITUITARY NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2;

EID: 84893163911     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082619     Document Type: Review

References (72)

1. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V et al. (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114: 336-344. PubMed: 20868211.
2. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90: 3089-3099. doi:10.1210/jc.2004-2231. PubMed: 15741248. (Pubitemid 40686369)
3. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol U S A 62: 1006-1012. doi:10.1016/j.jclinepi.2009.06.005.
4. Yacqub-Usman K, Richardson A, Duong CV, Clayton RN, Farrell WE (2012) The pituitary tumour epigenome: aberrations and prospects for targeted therapy. Nat Rev Endocrinol 8: 486-494. doi:10.1038/nrendo.2012.54. PubMed: 22525730.
5. Dudley KJ, Revill K, Clayton RN, Farrell WE (2009) Pituitary tumours: all silent on the epigenetics front. J Mol Endocrinol 42: 461-468. doi:10.1677/JME-09-0009. PubMed: 19208779.
6. Zhu X, Lee K, Asa SL, Ezzat S (2007) Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol 170: 1618-1628. PubMed: 17456767. (Pubitemid 47339306)
7. Dudley KJ, Revill K, Whitby P, Clayton RN, Farrell WE (2008) Genome-wide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors. Mol Cancer Res U S A 6: 1567-1574. doi:10.1158/1541-7786.MCR-08-0234.
8. Greally JM (2013) Bidding the CpG island goodbye. Elife 2: e00593. doi:10.7554/eLife.00593. PubMed: 23467495.
9. Fazzari MJ, Greally JM (2004) Epigenomics: beyond CpG islands. Nat Rev Genet 5: 446-455. doi:10.1038/nrg1349. PubMed: 15153997. (Pubitemid 38915411)
10. Zhu X, Asa SL, Ezzat S (2007) Ikaros is regulated through multiple histone modifications and deoxyribonucleic acid methylation in the pituitary. Mol Endocrinol 21: 1205-1215. doi:10.1210/me.2007-0053. PubMed: 17341593. (Pubitemid 46984769)
11. Mantovani G, Lania AG, Spada A (2010) GNAS imprinting and pituitary tumors. Mol Cell Endocrinol 326: 15-18. doi:10.1016/j.mce.2010.04.009. PubMed: 20398730.
12. Knudson AG Jr. (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820-823. doi:10.1073/pnas.68.4.820. PubMed: 5279523.
13. Herman-Bonert V, Fagin JA (1995) Molecular pathogenesis of pituitary tumours. Baillieres Clin Endocrinol Metab 9: 203-223. doi:10.1016/S0950-351X(95) 80290-8. PubMed: 7625983.
14. Davis JR, Farrell WE, Clayton RN (2001) Pituitary tumours. Reproduction U S A 121: 363-371. (Pubitemid 32243680)
15. Simpson DJ, Clayton RN, Farrell WE (2002) Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene U S A 21: 1217-1224. (Pubitemid 34185238)
16. Seemann N, Kuhn D, Wrocklage C, Keyvani K, Hackl W et al. (2001) CDKN2A/p16 inactivation is related to pituitary adenoma type and size. J Pathol 193: 491-497. PubMed: 11276008. (Pubitemid 32266818)
17. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196. PubMed: 9338076. (Pubitemid 27435555)
18. Farrell WE, Clayton RN (2003) Epigenetic change in pituitary tumorigenesis. Endocr Relat Cancer 10: 323-330. doi:10.1677/erc.0.0100323. PubMed: 12790793. (Pubitemid 36758658)
19. Farrell WE, Simpson DJ, Frost SJ, Clayton RN (1999) Methylation mechanisms in pituitary tumorigenesis. Endocr Relat Cancer 6: 437-447. doi:10.1677/erc.0.0060437. PubMed: 10730899. (Pubitemid 30048455)
20. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA et al. (1992) Effects of an Rb mutation in the mouse. Nature U S A 359: 295-300. doi:10.1038/359295a0.
21. Abd El-Moneim HM, Abd El-Rehim D (2009) Immunohistochemical and Molecular Study of p16INK4A Expression in Pituitary Adenoma. J Egypt Natl Cancer Inst U S A 21: 351-360.
22. Machiavelli G, Cotignola J, Danilowicz K, Carbonara C, Paes de Lima A et al. (2008) Expression of p16(INK4A) gene in human pituitary tumours. Pituitary 11: 71-75. doi:10.1007/s11102-007-0077-z. PubMed: 18058237.
23. Ruebel KH, Jin L, Zhang S, Scheithauer BW, Lloyd RV (2001) Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas. Endocr Pathol 12: 281-289. doi:10.1385/EP:12:3:281. PubMed: 11740049. (Pubitemid 34066749)
24. Woloschak M, Yu A, Xiao J, Post KD (1996) Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. Int J Cancer 67: 16-19. doi:10.1002/(SICI)1097-0215(19960703)67:1. PubMed: 8690518. (Pubitemid 26236062)
25. Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T et al. (2005) The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 64: 398-403. PubMed: 15892297. (Pubitemid 40629130)
26. Yoshimoto K, Tanaka C, Yamada S, Kimura T, Iwahana H et al. (1997) Infrequent mutations of p16INK4A and p15INK4B genes in human pituitary adenomas. Eur J Endocrinol 136: 74-80. doi:10.1530/eje.0.1360074. PubMed: 9037130.
27. Jaffrain-Rea ML, Ferretti E, Toniato E, Cannita K, Santoro A et al. (1999) p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours. Clin Endocrinol (Oxf) 51: 317-325. doi:10.1046/j.1365-2265. 1999.00774.x. PubMed: 10469011. (Pubitemid 29439051)
28. Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM et al. (2001) Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis U S A 22: 1149-1154. doi:10.1093/carcin/22.8. 1149. (Pubitemid 32737328)
29. Woloschak M, Yu A, Post KD (1997) Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol Carcinog 19: 221-224. doi:10.1002/(SICI)1098-2744(199708)19:4. PubMed: 9290697. (Pubitemid 27391999)
30. Bender CM, Pao MM, Jones PA (1998) Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58: 95-101. PubMed: 9426064. (Pubitemid 28027723)
31. Cryns VL, Alexander JM, Klibanski A, Arnold A (1993) The retinoblastoma gene in human pituitary tumors. J Clin Endocrinol Metab 77: 644-646. doi:10.1210/jc.77.3.644. PubMed: 7690360. (Pubitemid 23298641)
32. Woloschak M, Roberts JL, Post KD (1994) Loss of heterozygosity at the retinoblastoma locus in human pituitary tumors. Cancer 74: 693-696. PubMed: 8033049. (Pubitemid 24217635)
33. Zhu J, Leon SP, Beggs AH, Busque L, Gilliland DG et al. (1994) Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus. J Clin Endocrinol Metab 78: 922-927. doi:10.1210/jc.78.4.922. PubMed: 8157722. (Pubitemid 24118089)
34. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ et al. (1997) Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 82: 818-824. doi:10.1210/jc.82.3.818. PubMed: 9062489. (Pubitemid 27106594)
35. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF et al. (1995) Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 55: 1613-1616. PubMed: 7712461.
36. Simpson DJ, Bicknell JE, McNicol AM, Clayton RN, Farrell WE (1999) Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes Cancer U S A 24: 328-336. doi:10.1002/(SICI)1098-2264(199904) 24:4. (Pubitemid 29115871)
37. Farrell WE, Clayton RN (2000) Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol U S A 21: 174-198. doi:10.1006/frne.1999.0195. (Pubitemid 30495781)
38. Esteller M (2000) Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 36: 2294-2300. doi:10.1016/S0959-8049(00)00303-8. PubMed: 11094302.
39. Yoshino A, Katayama Y, Ogino A, Watanabe T, Yachi K et al. (2007) Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas. J Neurooncol 83: 153-162. doi:10.1007/s11060-006-9316-9. PubMed: 17216555. (Pubitemid 46784988)
40. Chesnokova V, Melmed S (2009) Pituitary tumour-transforming gene (PTTG) and pituitary senescence. Horm Res U S A 71 Suppl 2: 82-87. doi:10.1159/ 000192443. PubMed: 19407503.
41. Zhu X, Asa SL, Ezzat S (2008) Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin Cancer Res 14: 1984-1996. doi:10.1158/1078-0432.CCR-07-2003. PubMed: 18381936. (Pubitemid 351551107)
42. Ezzat S (2008) Epigenetic control in pituitary tumors. Endocr J 55: 951-957. PubMed: 18628575.
43. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M et al. (1999) Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 13: 156-166. doi:10.1210/me.13.1.156. PubMed: 9892021. (Pubitemid 29022288)
44. Panguluri SK, Kakar SS (2009) Effect of PTTG on endogenous gene expression in HEK 293 cells. BMC Genomics 10: 577. doi:10.1186/1471-2164-10-577. PubMed: 19958546.
45. Li T, Huang H, Huang B, Lu J (2009) Histone acetyltransferase p300 regulates the expression of human pituitary tumor transforming gene (hPTTG). J Genet Genomics u S A 36: 335-342. doi:10.1016/S1673-8527(08)60122-8. PubMed: 19539243.
46. Ebrahimi A, Schittenhelm J, Honegger J, Schluesener HJ (2011) Histone acetylation patterns of typical and atypical pituitary adenomas indicate epigenetic shift of these tumours. J Neuroendocrinol 23: 525-530. doi:10.1111/j.1365-2826.2011.02129.x. PubMed: 21453398.
47. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P et al. (2001) Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest U S A 107: R31-R36. doi:10.1172/JCI11892. (Pubitemid 32225362)
48. Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X et al. (2008) Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 93: 4119-4125. doi:10.1210/jc.2007- 2633. PubMed: 18628527.
49. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A (2005) Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab 90: 2179-2186. doi:10.1210/jc.2004- 1848. PubMed: 15644399. (Pubitemid 40586259)
50. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL et al. (2007) Activation of p53 by MEG3 non-coding RNA. J Biol Chem 282: 24731-24742. PubMed: 17569660. (Pubitemid 47347547)
51. Fedele M, Pierantoni GM, Visone R, Fusco A (2006) Critical role of the HMGA2 gene in pituitary adenomas. Cell Cycle 5: 2045-2048. doi:10.4161/cc.5.18. 3211. PubMed: 16969098. (Pubitemid 44553735)
52. Ezzat S, Yu S, Asa SL (2005) The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. Mol Endocrinol 19: 1004-1011. doi:10.1210/me.2004-0432. PubMed: 15618287. (Pubitemid 40397064)
53. Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A et al. (2008) Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 108: 736-745. PubMed: 18377253. (Pubitemid 351498969)
54. Zada G, Kelly DF, Cohan P, Wang C, Swerdloff R (2003) Endonasal transsphenoidal approach for pituitary adenomas and other sellar lesions: an assessment of efficacy, safety, and patient impressions. J Neurosurg 98: 350-358. PubMed: 12593622. (Pubitemid 36151031)
55. Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery U S A 33: 610-618; discussion: 8232800.
56. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. doi:10.1007/s00401-007-0243-4. PubMed: 17618441. (Pubitemid 47103521)
57. Bahar A, Simpson DJ, Cutty SJ, Bicknell JE, Hoban PR et al. (2004) Isolation and characterization of a novel pituitary tumor apoptosis gene. Mol Endocrinol 18: 1827-1839. doi:10.1210/me.2004-0087. PubMed: 15105437. (Pubitemid 38859588)
58. Bello MJ, De Campos JM, Isla A, Casartelli C, Rey JA (2006) Promoter CpG methylation of multiple genes in pituitary adenomas: frequent involvement of caspase-8. Oncol Rep 15: 443-448. PubMed: 16391867.
59. Zhu X, Mao X, Hurren R, Schimmer AD, Ezzat S et al. (2008) Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. J Clin Endocrinol Metab 93: 3610-3617. doi:10.1210/jc.2008-0578. PubMed: 18544619.
60. Ying J, Srivastava G, Hsieh WS, Gao Z, Murray P et al. (2005) The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res 11: 6442-6449. doi:10.1158/1078-0432.CCR-05- 0267. PubMed: 16166418. (Pubitemid 41338980)
61. So K, Tamura G, Honda T, Homma N, Waki T et al. (2006) Multiple tumor suppressor genes are increasingly methylated with age in non-neoplastic gastric epithelia. Cancer Sci 97: 1155-1158. PubMed: 16952303. (Pubitemid 44430640)
62. Simpson DJ, McNicol AM, Murray DC, Bahar A, Turner HE et al. (2004) Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease. Clin Cancer Res 10: 1780-1788. doi:10.1158/1078-0432.CCR-1127-3. PubMed: 15014032. (Pubitemid 38435569)
63. Xu B, Sano T, Yoshimoto K, Yamada S (2002) Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr Pathol 13: 341-351. doi:10.1385/EP:13:4:341. PubMed: 12665652. (Pubitemid 36237988)
64. Kawamoto H, Mizoue T, Arita K, Tominaga A, Eguchi K et al. (1997) Expression of epithelial cadherin and cavernous sinus invasion in human pituitary adenomas. J Neurooncol 34: 105-109. doi:10.1023/A:1005709014239. PubMed: 9210056. (Pubitemid 27271714)
65. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE (2000) Loss of pRb Expression in Pituitary Adenomas Is Associated with Methylation of the RB1 CpG Island. Cancer Research U S A 60: 1121-1216. PubMed: 10728677.
66. Ezzat S, Asa SL (2008) The emerging role of the Ikaros stem cell factor in the neuroendocrine system. J Mol Endocrinol 41: 45-51. doi:10.1677/JME-08- 0045. PubMed: 18515301.
67. Zhang X, Sun H, Danila D, Johnson S, Zhou Y et al. (2002) Loss of Expression of GADD45y, a Growth Inhibitory Gene, in Human Pituitary Adenomas: Implications for Tumorigenesis. Journal of Clinical Endocrinology and Metabolism 87 U; S A 3 (1262-1267)
68. Qian ZR, Sano T, Yoshimoto K, Yamada S, Ishizuka A et al. (2005) Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas 85. Laboratory Investigations. U S A. pp. 464-473.
69. Ezzat S, Zhu X, Loeper S, Fischer S, Asa SL (2006) Tumor-Derived Ikaros 6 Acetylates the Bcl-XL Promoter to Up-Regulate a Survival Signal in Pituitary Cells. Mol Endocrinol 20: 2976-2986. doi:10.1210/me.2006-0265. PubMed: 16873443. (Pubitemid 44833549)
70. Revill K, Dudley KJ, Clayton RN, McNicol AM, Farrell WE (2009) Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma. Endocr Relat Cancer 16: 537-548. doi:10.1677/ERC-09-0008. PubMed: 19218280.
71. Thomas L, Di Stefano AL, Ducray F (2013) Predictive biomarkers in adult gliomas: the present and future. Curr Opin Oncol U S A [Epub ahead of print].
72. Weichenhan D, Plass C (2013) The evolving epigenome. Hum Mol Genet 22: R1-R6. doi:10.1093/hmg/dds371. PubMed: 23900077.